Oncology, cancer prevention, tumor biology, and immunotherapy relevant to longevity
631 articoli
A phase I/II trial combining nivolumab, ipilimumab, and lurbinectedin for relapsed SCLC was terminated early, raising questions about feasibility.
A Swiss study of 100,000 cases over 40 years reveals colorectal cancer rising steadily in younger adults, with late diagnoses alarmingly common.
Stanford scientists used RFdiffusion and ProteinMPNN to build a compact α-helical TCR mimic with 9.5 nM affinity for a tumor antigen — and near-perfect peptide specificity.
A new machine learning tool called MaNeo scans tumor peptides to identify neoantigens that activate T cells against cancer while sparing healthy cells.
A Phase 2 trial testing AR blockade combined with PD-1 inhibition in treatment-emergent neuroendocrine prostate cancer was terminated early.
Sonrotoclax (Beqalzi), a next-gen BCL-2 inhibitor, wins accelerated FDA approval for relapsed or refractory MCL after BTK inhibitor failure.
A massive 857-study meta-analysis maps hepatitis B and C contributions to liver cancer across 81 countries, revealing stark regional disparities.
A Phase 2 trial combining adaptive stereotactic radiotherapy with IMSA101 and checkpoint inhibitors was halted after enrolling only 16 patients.
Pfizer's first-in-human trial of PF-07209960, a dual-action immunotherapy fusion protein, was terminated after enrolling 37 patients.
A phase 1 trial of a neoantigen DNA vaccine for glioblastoma found strong immune responses and survival rates exceeding historical benchmarks.
A new review reframes how myeloid cells fuel or fight tumors, pointing to plasticity — not just cell diversity — as the core therapeutic target.
A phase 3 trial finds nivolumab-based regimens offer no survival advantage over durvalumab for unresectable stage III NSCLC.
